FDA scales back use of antibiotics in livestock
Agency cites concerns about drug resistance
May 29, 2012 at 08:00 PM
12 minute read
When public health talks in the U.S. turn to antibiotic resistance, the conversation invariably leads to the use of antibiotics in food animals. The Food and Drug Administration (FDA) has confirmed that 80 percent of antibacterial drugs in the U.S. are sold for agricultural use. And Department of Agriculture (DOA) surveys have found that 83 percent to 84 percent of swine farms, cattle feedlots and sheep farms administer antimicrobials in feed or water, which can lead to inconsistent dosing. Many of those drugs are identical or closely related to human drugs.
In newly released voluntary guidance likely to significantly limit such use of antimicrobial drugs, the FDA cites numerous peer-reviewed scientific studies, along with a host of reports dating back to 1969 from groups including the World Health Organization and the Institute of Medicine, suggesting a relationship between the injudicious use of antibiotics in food-producing animals and antibiotic resistance.
Industry groups have countered the FDA with numbers that downplay the link. But Sean Minahan, a partner at Lamson, Dugan and Murray in Omaha, Neb., says that whether the FDA's findings are right or wrong, at this point the momentum is in its favor. The research to support limitations on antibiotic use in animals is building, the Obama administration supports such limits and the organic and all-natural food movements are huge and growing.
On April 11, the FDA released three documents addressing the responsible use of medically important antibiotics in food-producing animals. Implementation of these policies would eliminate nontherapeutic uses of medically important antibiotics in animal agriculture and require veterinary supervision of therapeutic uses.
“That is a major change, and it is a policy that would align animal-health uses of antibiotics with the way they're used in human health,” says Ron Phillips, vice president for legislative and public affairs for the Animal Health Institute (AHI), an industry group that represents animal drug developers and producers.
Limited Use
The FDA's April guidance eliminates all nontherapeutic uses of antibiotics in food-producing animals, limiting use to what is “considered necessary for assuring animal health,” which it specifically limits to treatment, control and prevention. It also directs that antimicrobials—which for decades have been available over-the-counter to livestock producers—now should be used only with veterinary oversight or consultation.
Antibiotics the FDA has approved for animal use currently fall under four label claims—treatment, control, prevention and growth promotion, or the claim that use of a drug leads to greater growth with less feed. The guidance eliminates this last claim (see “Label Changes”).
Nontherapeutic use of antibiotics is common among livestock producers, who administer low-level doses of antibiotics to entire herds or flocks of animals for long durations, usually through feed, without targeting any specific disease. Low doses of antibiotics are linked to resistance. Given such long-term and widespread use, the FDA says growth promotion represents a substantial proportion of the overall use of antibiotics in agriculture, although it has no specific data.
There has been some concern among public health groups over the FDA's continued approval of antibiotics for preventive use. Dr. Robert S. Lawrence, professor at the Johns Hopkins Bloomberg School of Public Health, wrote in a piece for The Atlantic that like growth promotion, preventive use involves low doses “that are equally culpable in the development of antibiotic resistance.” The FDA maintains that in some cases preventive use is “necessary and judicious” under veterinary supervision.
Public health groups also have expressed concern that the guidance is voluntary rather than compulsory.
“In the FDA world, 'voluntary' means something different,” Phillips rebuts. “The guidance means that this is the FDA's approach, and basically that if you want to work with the FDA, this is the way you're going to do it.”
The FDA has said it will assess adoption levels after a three-year period.
Veterinary Demand
The FDA calls for veterinarians to supervise use of antibiotics that go into animal feed and requires a statement from them stipulating details of use—how long it is given, how much is administered and how it's distributed among herds, for example. “It becomes very cumbersome, almost tedious,” Minahan says of the process. Livestock producers fear their operating costs will grow substantially because of an increased need for veterinary oversight. What's more, Minahan says, the increased demand for veterinary supervision could cause a shortage of care. In many regions, large-animal veterinarians are hard to find in the first place.
“For small producers who don't have a vet on staff … or even those in really remote areas without easy veterinary access, this has the potential to be a big issue,” says Liz Wagstrom, chief veterinarian for the National Pork Producers Council.
Livestock producers also fear that by limiting the use of antibiotics, instances of illness and disease in animals will rise, which would lead to producers treating them with antibiotics in higher dosages than would have been used for growth promotion. “Is it better to use a low dose in an entire population or to use increased doses at select times? The science gets hazy here,” Minahan says.
Continuing Trend
Not all producers oppose or fear the changes. Stephen McDonnell, the founder and CEO of Applegate Farms, an organic meat and cheese producer that works with a network of nearly 1,000 family farmers, says his company has seen success and growth over 25 years using an antibiotic-free model. “Producers need to look at these changes as an opportunity, not a challenge,” he said in an email.
Wagstrom advises that producers do anything they can to improve management, which is how Danish producers say they survived the country's similar 1998 ban on nontherapeutic use.
The FDA's April guidance is another step in its evolving approach toward antibiotics use in livestock. In January, it took the small step of banning certain off-label animal uses of cephalosporins, a class of antibiotics used in both animals and humans. Minahan says that ban got the ball rolling.
“I tell my clients to plan ahead and start transitioning their production [according to what] they think the FDA's going to do in the future,” Minahan says. “Unless you come up with something that shows antibiotics are not creating antibiotic-resistant bacteria, you're going to have a hard time reversing this trend.”
When public health talks in the U.S. turn to antibiotic resistance, the conversation invariably leads to the use of antibiotics in food animals. The Food and Drug Administration (FDA) has confirmed that 80 percent of antibacterial drugs in the U.S. are sold for agricultural use. And Department of Agriculture (DOA) surveys have found that 83 percent to 84 percent of swine farms, cattle feedlots and sheep farms administer antimicrobials in feed or water, which can lead to inconsistent dosing. Many of those drugs are identical or closely related to human drugs.
In newly released voluntary guidance likely to significantly limit such use of antimicrobial drugs, the FDA cites numerous peer-reviewed scientific studies, along with a host of reports dating back to 1969 from groups including the World Health Organization and the Institute of Medicine, suggesting a relationship between the injudicious use of antibiotics in food-producing animals and antibiotic resistance.
Industry groups have countered the FDA with numbers that downplay the link. But Sean Minahan, a partner at Lamson, Dugan and Murray in Omaha, Neb., says that whether the FDA's findings are right or wrong, at this point the momentum is in its favor. The research to support limitations on antibiotic use in animals is building, the Obama administration supports such limits and the organic and all-natural food movements are huge and growing.
On April 11, the FDA released three documents addressing the responsible use of medically important antibiotics in food-producing animals. Implementation of these policies would eliminate nontherapeutic uses of medically important antibiotics in animal agriculture and require veterinary supervision of therapeutic uses.
“That is a major change, and it is a policy that would align animal-health uses of antibiotics with the way they're used in human health,” says Ron Phillips, vice president for legislative and public affairs for the Animal Health Institute (AHI), an industry group that represents animal drug developers and producers.
Limited Use
The FDA's April guidance eliminates all nontherapeutic uses of antibiotics in food-producing animals, limiting use to what is “considered necessary for assuring animal health,” which it specifically limits to treatment, control and prevention. It also directs that antimicrobials—which for decades have been available over-the-counter to livestock producers—now should be used only with veterinary oversight or consultation.
Antibiotics the FDA has approved for animal use currently fall under four label claims—treatment, control, prevention and growth promotion, or the claim that use of a drug leads to greater growth with less feed. The guidance eliminates this last claim (see “Label Changes”).
Nontherapeutic use of antibiotics is common among livestock producers, who administer low-level doses of antibiotics to entire herds or flocks of animals for long durations, usually through feed, without targeting any specific disease. Low doses of antibiotics are linked to resistance. Given such long-term and widespread use, the FDA says growth promotion represents a substantial proportion of the overall use of antibiotics in agriculture, although it has no specific data.
There has been some concern among public health groups over the FDA's continued approval of antibiotics for preventive use. Dr. Robert S. Lawrence, professor at the Johns Hopkins Bloomberg School of Public Health, wrote in a piece for The Atlantic that like growth promotion, preventive use involves low doses “that are equally culpable in the development of antibiotic resistance.” The FDA maintains that in some cases preventive use is “necessary and judicious” under veterinary supervision.
Public health groups also have expressed concern that the guidance is voluntary rather than compulsory.
“In the FDA world, 'voluntary' means something different,” Phillips rebuts. “The guidance means that this is the FDA's approach, and basically that if you want to work with the FDA, this is the way you're going to do it.”
The FDA has said it will assess adoption levels after a three-year period.
Veterinary Demand
The FDA calls for veterinarians to supervise use of antibiotics that go into animal feed and requires a statement from them stipulating details of use—how long it is given, how much is administered and how it's distributed among herds, for example. “It becomes very cumbersome, almost tedious,” Minahan says of the process. Livestock producers fear their operating costs will grow substantially because of an increased need for veterinary oversight. What's more, Minahan says, the increased demand for veterinary supervision could cause a shortage of care. In many regions, large-animal veterinarians are hard to find in the first place.
“For small producers who don't have a vet on staff … or even those in really remote areas without easy veterinary access, this has the potential to be a big issue,” says Liz Wagstrom, chief veterinarian for the National Pork Producers Council.
Livestock producers also fear that by limiting the use of antibiotics, instances of illness and disease in animals will rise, which would lead to producers treating them with antibiotics in higher dosages than would have been used for growth promotion. “Is it better to use a low dose in an entire population or to use increased doses at select times? The science gets hazy here,” Minahan says.
Continuing Trend
Not all producers oppose or fear the changes. Stephen McDonnell, the founder and CEO of Applegate Farms, an organic meat and cheese producer that works with a network of nearly 1,000 family farmers, says his company has seen success and growth over 25 years using an antibiotic-free model. “Producers need to look at these changes as an opportunity, not a challenge,” he said in an email.
Wagstrom advises that producers do anything they can to improve management, which is how Danish producers say they survived the country's similar 1998 ban on nontherapeutic use.
The FDA's April guidance is another step in its evolving approach toward antibiotics use in livestock. In January, it took the small step of banning certain off-label animal uses of cephalosporins, a class of antibiotics used in both animals and humans. Minahan says that ban got the ball rolling.
“I tell my clients to plan ahead and start transitioning their production [according to what] they think the FDA's going to do in the future,” Minahan says. “Unless you come up with something that shows antibiotics are not creating antibiotic-resistant bacteria, you're going to have a hard time reversing this trend.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllThe FTC's Rebecca Slaughter Wants Fair Competition, and a Good Night's Sleep
New Merger-Review Process Could Doom Some Deals, Add Headaches, Subjectivity to Others
7 minute readFormer CFTC Chair and SEC Commissioner Chart Election's Impact on Crypto and Capital Markets
4 minute readTrending Stories
- 1Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict
- 2Pass Rate on California's July 2024 Bar Exam Ticks Up to 53.8%
- 3TEST TEST
- 4High Court Asked To Review DOJ's 'Illusory Promise,' Religious Charter School, Meta Class Action
- 5'Rampant Piracy': US Record Labels File Copyright Suit Against French Distributor Believe
- 6$5.5M Miami Verdict: Meet the Lawyers Behind the Slip-and-Fall Suit
Who Got The Work
Michael G. Bongiorno, Andrew Scott Dulberg and Elizabeth E. Driscoll from Wilmer Cutler Pickering Hale and Dorr have stepped in to represent Symbotic Inc., an A.I.-enabled technology platform that focuses on increasing supply chain efficiency, and other defendants in a pending shareholder derivative lawsuit. The case, filed Oct. 2 in Massachusetts District Court by the Brown Law Firm on behalf of Stephen Austen, accuses certain officers and directors of misleading investors in regard to Symbotic's potential for margin growth by failing to disclose that the company was not equipped to timely deploy its systems or manage expenses through project delays. The case, assigned to U.S. District Judge Nathaniel M. Gorton, is 1:24-cv-12522, Austen v. Cohen et al.
Who Got The Work
Edmund Polubinski and Marie Killmond of Davis Polk & Wardwell have entered appearances for data platform software development company MongoDB and other defendants in a pending shareholder derivative lawsuit. The action, filed Oct. 7 in New York Southern District Court by the Brown Law Firm, accuses the company's directors and/or officers of falsely expressing confidence in the company’s restructuring of its sales incentive plan and downplaying the severity of decreases in its upfront commitments. The case is 1:24-cv-07594, Roy v. Ittycheria et al.
Who Got The Work
Amy O. Bruchs and Kurt F. Ellison of Michael Best & Friedrich have entered appearances for Epic Systems Corp. in a pending employment discrimination lawsuit. The suit was filed Sept. 7 in Wisconsin Western District Court by Levine Eisberner LLC and Siri & Glimstad on behalf of a project manager who claims that he was wrongfully terminated after applying for a religious exemption to the defendant's COVID-19 vaccine mandate. The case, assigned to U.S. Magistrate Judge Anita Marie Boor, is 3:24-cv-00630, Secker, Nathan v. Epic Systems Corporation.
Who Got The Work
David X. Sullivan, Thomas J. Finn and Gregory A. Hall from McCarter & English have entered appearances for Sunrun Installation Services in a pending civil rights lawsuit. The complaint was filed Sept. 4 in Connecticut District Court by attorney Robert M. Berke on behalf of former employee George Edward Steins, who was arrested and charged with employing an unregistered home improvement salesperson. The complaint alleges that had Sunrun informed the Connecticut Department of Consumer Protection that the plaintiff's employment had ended in 2017 and that he no longer held Sunrun's home improvement contractor license, he would not have been hit with charges, which were dismissed in May 2024. The case, assigned to U.S. District Judge Jeffrey A. Meyer, is 3:24-cv-01423, Steins v. Sunrun, Inc. et al.
Who Got The Work
Greenberg Traurig shareholder Joshua L. Raskin has entered an appearance for boohoo.com UK Ltd. in a pending patent infringement lawsuit. The suit, filed Sept. 3 in Texas Eastern District Court by Rozier Hardt McDonough on behalf of Alto Dynamics, asserts five patents related to an online shopping platform. The case, assigned to U.S. District Judge Rodney Gilstrap, is 2:24-cv-00719, Alto Dynamics, LLC v. boohoo.com UK Limited.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250